Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $157.00 by Analysts at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective reduced by TD Cowen from $175.00 to $157.00 in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $170.00 to $174.00 and gave the stock an overweight rating in a report on Wednesday, August 21st. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the stock a buy rating in a research note on Tuesday, August 13th. Morgan Stanley raised their price objective on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an equal weight rating in a research note on Thursday, May 16th. Wells Fargo & Company lowered their target price on shares of Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating on the stock in a research report on Wednesday. Finally, Cantor Fitzgerald reduced their price target on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating for the company in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of Moderate Buy and a consensus target price of $187.08.

Ascendis Pharma A/S Stock Up 0.1 %

NASDAQ ASND opened at $119.15 on Wednesday. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The firm has a 50-day moving average price of $134.38 and a 200 day moving average price of $138.07. The stock has a market capitalization of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.

Institutional Trading of Ascendis Pharma A/S

A number of large investors have recently made changes to their positions in ASND. GAMMA Investing LLC acquired a new stake in Ascendis Pharma A/S during the fourth quarter worth approximately $25,000. Private Ocean LLC purchased a new position in shares of Ascendis Pharma A/S during the 1st quarter worth $36,000. Quadrant Capital Group LLC boosted its holdings in shares of Ascendis Pharma A/S by 90.4% during the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. Finally, Barometer Capital Management Inc. acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at $126,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.